Vanguard Group
ARDS

Vanguard Group’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Vanguard Group’s Portfolio ARDS Stock Details ARDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-136,197
Closed -$29.9K – 4628
2023
Q2 		$29.9K Sell
136,197
-388,959
-74% -$89.6K ﹤0.01% 4499
2023
Q1 		$165K Buy
525,156
+703
+0.1% +$510 ﹤0.01% 4343
2022
Q4 		$619K Buy
524,453
+331
+0.1% +$320 ﹤0.01% 4044
2022
Q3 		$488K Hold
524,122
– – ﹤0.01% 4216
2022
Q2 		$577K Hold
524,122
– – ﹤0.01% 4254
2022
Q1 		$922K Buy
524,122
+16,785
+3% +$31.8K ﹤0.01% 4233
2021
Q4 		$1.18M Buy
507,337
+337,800
+199% +$961K ﹤0.01% 4218
2021
Q3 		$624K Buy
169,537
+9,591
+6% +$44.3K ﹤0.01% 4344
2021
Q2 		$1.18M Buy
159,946
+10,288
+7% +$64.3K ﹤0.01% 4118
2021
Q1 		$883K Buy
149,658
+2,234
+2% +$15.1K ﹤0.01% 4041
2020
Q4 		$894K Hold
147,424
– – ﹤0.01% 3854
2020
Q3 		$1.04M Buy
147,424
+73,122
+98% +$510K ﹤0.01% 3650
2020
Q2 		$493K Hold
74,302
– – ﹤0.01% 3771
2020
Q1 		$429K Hold
74,302
– – ﹤0.01% 3704
2019
Q4 		$331K Sell
74,302
-7,664
-9% -$40.4K ﹤0.01% 3870
2019
Q3 		$551K Buy
81,966
+38,685
+89% +$354K ﹤0.01% 3795
2019
Q2 		$440K Sell
43,281
-2,384
-5% -$22.9K ﹤0.01% 3850
2019
Q1 		$502K Buy
+45,665
New +$422K ﹤0.01% 3769

Other funds holding ARDS

WA
Wealth Architects Mountain View, California $1.27B AUM 36.93% 1-Year Est. Return

Vanguard Group's ARDS Position: Q3 2023 in Review

Vanguard Group sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q3 2023, closing a stake of 136,197 shares — an estimated $29.9K sold.

Vanguard Group first reported a position in ARDS in Q1 2019 and held it in 18 quarters. The position peaked at $1.18M in Q2 2021. 1 fund tracked by Wall St. Rank holds ARDS as of Q3 2023.

  • Vanguard Group reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Vanguard Group sold 136,197 Aridis Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $29.9K.
  • Vanguard Group first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q1 2019 and held it in 18 quarters.
  • Vanguard Group's Aridis Pharmaceuticals Inc. Common Stock position peaked at $1.18M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q3 2023.

Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.